Moderna Stock Is 4.78% Up At Session Start On Friday
Via News Editorial Team
November 20, 2020

According to today's article on Bloomberg Quint, "EU Could Approve BioNTech, Moderna Vaccines in December."
Shares of Moderna rose 4.78% to $97.2 at 10:48 EST on Friday. The Nasdaq Stock Market is rising 0.06% to $11911.7, on what seems, so far, a somewhat positive trend trading session on The Nasdaq Stock Market.
According to yesterday's article on Bloomberg Quint, "Moderna Vaccine Production Is Gearing Up, Partner Lonza Says."
Moderna's last close was $92.77, below its 52-week high of $103.2.
Moderna's sales growth is 1216.8% for the ongoing quarter and 2299% for the next. The company's growth estimates for the current quarter is a negative 67.6% and positive 142.9% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna's stock is valued at $97.2 at 10:48 EST, under its 52-week high of $103.2 and way higher than its 52-week low of $17.68.
Moderna's worth is way above its 50-day moving average of $75.37 and way above its 200-day moving average of $68.93.
Moderna vaccine found highly effective at preventing covid. According to Bloomberg Quint on Mon Nov 16, "Moderna shares rised more than 9% in pre-market U.S."
According to Bloomberg Quint on Tue Nov 17, "Moderna Vaccine Offers Possible Antidote to Deep-Freeze Problem."
